Expertise in
17
conditions

Dr. Carla B. Golden

Hematology | Oncology
UCSF Benioff Children's Hospital Oakland
747 52nd St, 
Oakland, CA 
Clinical Trials:Currently Recruiting for 3 Trials
Expertise in
17
conditions
UCSF Benioff Children's Hospital Oakland
747 52nd St, 
Oakland, CA 

Overview

Carla Golden is a Hematologist and an Oncologist practicing medicine in Oakland, California.

Dr. Golden is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Hepatoblastoma, Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 57 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

UCSF Benioff Children's Hospital Oakland
747 52nd St, Oakland, CA 94609

Additional Areas of Focus

Dr. Golden has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

57 Clinical Trials

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
View 7 Less Clinical Trials

15 Total Publications

Routine Screening for Neuroblastoma in Harlequin Syndrome Without Otherwise Known Etiology.
Routine Screening for Neuroblastoma in Harlequin Syndrome Without Otherwise Known Etiology.
Journal: Pediatric blood & cancer
Published: November 02, 2024
Similar Doctors
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (0.1 miles away)
510-428-3372
Languages Spoken:
English
See accepted insurances

Elliott Vichinsky is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Vichinsky is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
13
conditions
Dr. Ashutosh P. Lal
Hematology | Oncology
Expertise in
13
conditions
Dr. Ashutosh P. Lal
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (0.1 miles away)
510-428-3374
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Offers Telehealth

Ashutosh Lal is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Lal is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Thalassemia, Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Expertise in
10
conditions
Dr. Mark C. Walters
Hematology | Oncology
Expertise in
10
conditions
Dr. Mark C. Walters
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (0.1 miles away)
510-428-3374
Languages Spoken:
English
See accepted insurances

Mark Walters is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Walters is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Congenital Hemolytic Anemia, Sickle Cell Disease, Hemolytic Anemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Carla B. Golden

How do I make an appointment with Dr. Carla B. Golden?

You can book an appointment with Dr. Carla B. Golden by calling their office at 510-428-3372. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Carla B. Golden a top-rated expert for Hepatoblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Carla B. Golden is classified as an Advanced expert for Hepatoblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Carla B. Golden specialize in?

While Dr. Carla B. Golden is a Hematology, they have specific expertise in Hepatoblastoma, Langerhans Cell Histiocytosis, and Reticulohistiocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Carla B. Golden participate in research or clinical trials?

Yes. Dr. Carla B. Golden has published 15 articles and abstracts on conditions like Hepatoblastoma. You can view a list of Dr. Carla B. Golden's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Carla B. Golden accept my insurance?

Dr. Carla B. Golden accepts most major insurance plans, including Humana and Medicaid. We recommend calling the office directly at 510-428-3372 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Golden's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile